Overview

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Status:
Active, not recruiting

Trial end date:
2022-10-06

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborator:

Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Capecitabine
Fluorouracil
Ipilimumab
Leucovorin
Nivolumab
Oxaliplatin